Trump has begun another trade war. Here's a timeline of how we got here
Canada's leader laments lost friendship with US in town that sheltered stranded Americans after 9/11
Chinese EV giant BYD's fourth-quarter profit leaps 73%
You're an American in another land? Prepare to talk about the why and how of Trump 2.0
Chalk talk: Star power, top teams and No. 5 seeds headline the women's March Madness Sweet 16
Purdue returns to Sweet 16 with 76-62 win over McNeese in March Madness
(Reuters) - Danish drugmaker Novo Nordisk said on Monday several hundred counterfeit units of its diabetes drug Ozempic were being distributed outside its authorized supply chain in the United States.
The country's health regulator seized the counterfeit injections on April 9 and is investigating them.
Surging demand for Novo's Ozempic, chemically known as semaglutide, has given rise to concerns about unregulated, compounded and counterfeit medicines. Its weight-loss drug Wegovy also has the same active ingredient.
As the investigation continues, further analyses, including extensive visual examination and chemical testing of the seized, counterfeit product is underway. The U.S. Food and Drug Administration and Novo Nordisk do not yet have information about the drugs' identity, quality, or safety, the regulator said on its website.
Novo has advised retail pharmacies to purchase authentic Ozempic injections from authorized distributors and urged patients to check their product for any signs of counterfeiting before using.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shailesh Kuber and Shilpi Majumdar)
